Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China · Delayed Price · Currency is CNY 8.50
-0.14 (-1.62%)
Feb 3, 2026, 3:00 PM CST
SHA:603567 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,568 | 2,677 | 3,084 | 4,199 | 4,120 | 3,390 |
Other Revenue | 26.93 | 26.93 | 54.11 | 14.68 | 6.5 | 14.22 |
| 1,595 | 2,704 | 3,138 | 4,214 | 4,127 | 3,404 | |
Revenue Growth (YoY) | -48.84% | -13.84% | -25.53% | 2.12% | 21.24% | 3.40% |
Cost of Revenue | 973.53 | 1,334 | 1,846 | 3,539 | 2,829 | 1,515 |
Gross Profit | 621.38 | 1,370 | 1,292 | 675.25 | 1,298 | 1,888 |
Selling, General & Admin | 475.37 | 575.22 | 979.01 | 915.17 | 952.16 | 1,054 |
Research & Development | 41.72 | 37.99 | 80.22 | 70.95 | 55.23 | 81.34 |
Other Operating Expenses | 22.5 | 36.03 | 43.79 | -64.36 | -24.14 | 132.34 |
Operating Expenses | 792.32 | 767.06 | 1,107 | 891.96 | 1,028 | 1,303 |
Operating Income | -170.93 | 602.9 | 185.52 | -216.71 | 270.38 | 585.35 |
Interest Expense | -147.7 | -137.09 | -135.41 | -138.68 | -144.79 | -149.61 |
Interest & Investment Income | 9.29 | 22.69 | 471.68 | 38.06 | 251.32 | 31.87 |
Currency Exchange Gain (Loss) | - | - | - | -0 | -0 | -0 |
Other Non Operating Income (Expenses) | 13.24 | 9.22 | -88.59 | 26.83 | -22.32 | -1.85 |
EBT Excluding Unusual Items | -296.11 | 497.73 | 433.2 | -290.5 | 354.6 | 465.76 |
Impairment of Goodwill | - | - | -2.4 | -1.28 | - | - |
Gain (Loss) on Sale of Investments | -10.54 | -9.69 | 0.6 | -1.75 | -0.15 | -16.98 |
Gain (Loss) on Sale of Assets | -0.69 | -1.68 | -0.26 | 39.33 | -1.11 | -0.21 |
Asset Writedown | -105.19 | -0.63 | -1.51 | - | -0.09 | - |
Other Unusual Items | 32.36 | 37.75 | 48.72 | 552.68 | 101.49 | 88.68 |
Pretax Income | -380.16 | 523.47 | 478.35 | 298.48 | 454.75 | 537.25 |
Income Tax Expense | -44.48 | 87.08 | 10.76 | 107.55 | 121.99 | 99.75 |
Earnings From Continuing Operations | -335.68 | 436.39 | 467.59 | 190.93 | 332.76 | 437.5 |
Minority Interest in Earnings | 3.07 | 1.82 | 5.15 | -5.49 | -0.66 | -1.22 |
Net Income | -332.62 | 438.22 | 472.74 | 185.44 | 332.1 | 436.29 |
Net Income to Common | -332.62 | 438.22 | 472.74 | 185.44 | 332.1 | 436.29 |
Net Income Growth | - | -7.30% | 154.93% | -44.16% | -23.88% | 6.76% |
Shares Outstanding (Basic) | 940 | 940 | 939 | 941 | 865 | 849 |
Shares Outstanding (Diluted) | 940 | 940 | 940 | 941 | 865 | 849 |
Shares Change (YoY) | -0.12% | -0.01% | -0.14% | 8.87% | 1.82% | -0.01% |
EPS (Basic) | -0.35 | 0.47 | 0.50 | 0.20 | 0.38 | 0.51 |
EPS (Diluted) | -0.35 | 0.47 | 0.50 | 0.20 | 0.38 | 0.51 |
EPS Growth | - | -7.30% | 155.28% | -48.71% | -25.24% | 6.78% |
Free Cash Flow | 372.73 | -24.84 | -573.38 | -731.07 | -882.57 | -713.47 |
Free Cash Flow Per Share | 0.40 | -0.03 | -0.61 | -0.78 | -1.02 | -0.84 |
Dividend Per Share | 0.150 | 0.150 | 0.200 | 0.028 | 0.106 | - |
Dividend Growth | -25.00% | -25.00% | 614.29% | -73.58% | - | - |
Gross Margin | 38.96% | 50.67% | 41.18% | 16.02% | 31.45% | 55.48% |
Operating Margin | -10.72% | 22.30% | 5.91% | -5.14% | 6.55% | 17.20% |
Profit Margin | -20.86% | 16.21% | 15.06% | 4.40% | 8.05% | 12.82% |
Free Cash Flow Margin | 23.37% | -0.92% | -18.27% | -17.35% | -21.39% | -20.96% |
EBITDA | -35.46 | 756.94 | 364.32 | -59.75 | 405.93 | 741.23 |
EBITDA Margin | -2.22% | 27.99% | 11.61% | -1.42% | 9.84% | 21.78% |
D&A For EBITDA | 135.47 | 154.04 | 178.8 | 156.95 | 135.55 | 155.89 |
EBIT | -170.93 | 602.9 | 185.52 | -216.71 | 270.38 | 585.35 |
EBIT Margin | -10.72% | 22.30% | 5.91% | -5.14% | 6.55% | 17.20% |
Effective Tax Rate | - | 16.63% | 2.25% | 36.03% | 26.82% | 18.57% |
Revenue as Reported | 1,596 | 2,707 | 3,144 | 4,219 | 4,130 | 3,411 |
Advertising Expenses | - | 15.94 | 10.42 | 3.57 | 2.17 | 3.74 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.